期刊文献+

缬沙坦胶囊治疗糖尿病肾病效果观察 被引量:1

下载PDF
导出
摘要 目的:研究和探讨缬沙坦胶囊治疗糖尿病肾病的临床治疗效果。方法:本次实验利用回顾性分析方法,研究对象为我院心血管科于2013年1月1日~2014年7月31日收治的188例糖尿病肾病患者。按照治疗方法不同分为治疗组和对照组,每组各94例。两组患者均注射胰岛素进行常规降血糖治疗,同时口服利尿剂进行常规降压治疗,治疗组患者在上述治疗基础上再口服缬沙坦胶囊。观察行不同方法治疗的两组患者的治疗效果,探析缬沙坦胶囊治疗糖尿病肾病的临床效果。结果:治疗组的总有效率为91.49%,对照组的总有效率为74.47%,治疗组的总有效率显著高于对照组,两组比较差异显著(P〈0.05)。结论:口服缬沙坦胶囊治疗糖尿病肾病能够显著提高治疗总有效率,减轻患者临床症状,使尿白蛋白量以及血压恢复正常,值得临床推广。
作者 刘艳红
出处 《北方药学》 2015年第1期47-47,共1页 Journal of North Pharmacy
  • 相关文献

参考文献2

二级参考文献19

  • 1WHO/ISH Guidelines Committee.1999 World Health Organization Intemational Society of Hypertension Guide Lines for the Management of Hypertension[J].Blood Press Supple,1999,1:9-43.
  • 2Alourciere Y,Belanger A.Long-term comparison of valsartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy[J].Kidney Int,2000,58(2):762-769.
  • 3Makino H,Nakamura Y,Wada J.Remission and regression of diabetic nephropathy[J].Hypertens Res,2003,26(7):515-519.
  • 4费震宇,王文健,陈响中.三七用于冠心病治疗的药理研究[J].时珍国药研究,1997,8(1):17-18. 被引量:55
  • 5Yang W Y,Lu J M,Weng J P,et al.Prevalence of Diabetes among Men and Women in China[J].N Engl J Med,2010,25;362(12):1090-1101.
  • 6Reboldi G,Gentile G,Angeli F,et al.Microalbuminuria and hypertension[J].MinervaMed,2005,96(4):261-275.
  • 7Li X C,Widdop R E.AT2 receptor-mediated vasodilatation is unmasked by AT1 receptor blockade in conscious SHR[J].Br J Pharmacol,2004,142(5):821-830.
  • 8Fujino,YoshihiroKiya,YukioTominaga.etal,A small difference in the molecular structure of angiotensin Ⅱ receptor blockers induces AT1 receptor-dependent and-independent beneficial effects[J].Hypertens Res,2010,33(10):1044-1052.
  • 9Schinichiro Miura.Management of hypertensive therapy in patients CKD by JSH2009:mechanism of renal protection by irbesartan[J].Ther Res,2009,30(4):493-499.
  • 10Belz G G,Butzer R,Kober S.et al.Time course and extent of angiotensin Ⅱ antagonism after irbesartan,losartan,and valsartan in humans assessed by angiotensin Ⅱ dose response and radioligand receptor assay[J].Clin Pharmacol Ther,1999,66(4):367-373.

同被引文献10

  • 1Flesch G, Miiller P, Lloyd P. Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin 1I receptor ant-agonist, in man [J]. Eur J Clin Pharmacol, 1997, 52 ( 2 ) : 115-120.
  • 2Park Y J, Lee HK, Im YB, ct al. Improved pH-independent dissolution and oral absorption of valsartan via the preparation of solid dispersion [J]. Arch Pharm Res, 2010, 33 ( 8 ) : 1235-1240.
  • 3Yan YD, Sung JH, Kim KK, et al. Novel valsartan-loaded solid dispersion with enhanced bioavailability and no crystalline changes [J]. Int J Pharm, 2012, 422 ( 1-2 ) : 202-210.
  • 4Dixit AR, Rajput S J, Patel SG. Preparation and bioavaila- bility assessment of SMEDDS containing valsartan [J]. AAPS PharmSciTech, 2010, 11 ( 1 ) : 314-321.
  • 5Zhang YZ, Wang JC, Bai XY, et al. Mesoporous silica na- nopartieles for increasing the oral bioavailability and permeati- on of poorly water soluble drugs [J]. Mol Pharm, 2012, 9( 3 ): 505-513.
  • 6Sun L, Wang Y, Jiang T, et al. Novel chitosan-functiona- lized spherical nanosilica matrix as an oral sustained drug de-livery system for poorly water-soluble drug carvedilol [J]. Acs Appl Mater Inter, 2013, 5 (1) : 103-113.
  • 7MeUaerts R, Jammaer JAG, Van Speybreck M, et al. Physi- cal state of poorly water soluble therapeutic molecules loaded into SBA-15 ordered mesoporous silica carriers: A case study with itraconazole and ibuprofen [J]. Langmuir, 2008, 24( 16 ): 8651-8659.
  • 8Heikkil~i T, Salonen J, Tuura J, et al. Evaluation of meso- porous TCPSi, MCM-41, SBA-15, and TUD-1 materials as API carriers for oral drug delivery [J]. Drug Deliv, 2007, 14 (6) : 337-347.
  • 9Xu W, Riikonen J, Lehto VP. Mesoporous systems for poorly soluble drugs [J]. Int JPharm, 2013, 453 ( 1 ) : 181-197.
  • 10Yan YD, Sung JH, Kim KK, et al. Novel valsartan-loaded solid dispersion with enhanced bioavailability and no crystalline changes [J]. Int J Pharm, 2012, 422 (1-2 ) : 202-210.

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部